Table 2.

Prevalence of AHD in included studies.

First authors surname, year, country	Number with CD4	Number with CD4 < 200	% CD4 < 200	% WHO Stage 3/4	Stage 3/4 defining disease	Duration of follow‐up (months)	AHD Prevalence
May et al. 2010 [25]; Cote d' Ivoire, South Africa, Malawi	11,153	9471	84.9%	85.0%	Severe anaemia 37%	12	85%
Auld et al. 2011 [17]; Mozambique	2596	1500	57.8%	53.0%	TB 11%	Median 1.3 years (0.7, 2.2)	57%
Mills et al. 2011 [26]; Uganda	18,498	9804	53.0%	42.0%	TB 5%	Median months 32 (20, 47)	53%
Wandeler et al. 2012 [27]; Zimbabwe, Mozambique, Lesotho		—	—	70.4%	—	36	70.4%
Cornell et al. 2012 [28]; South Africa	39,990	35,191	88.0%	79.0%		36	88.0%
Chalamilla et al. 2012 [29]; Tanzania	8655	6855	78.9%	79.2%	TB 13.4%	36	79.2%
Fatti et al. 2014 [30]; South Africa	90,071	63,410	70.0%	47.0%	—	60	70.0%
Aliyu et al. 2014 [31]; Nigeria	790	529	61.0%	67.0%	—		67.0%
Melaku et al. 2015 [32]; Ethiopia	44,132	28,686	59.0%	65.0%	—	36	65.0%
Mhozya et al. 2015 [33]; Tanzania	243	153	41.8%	62.6%	—	—	63.0%
Mutimura et al. 2015 [34]; Rwanda	4486	158	21.0%	27.0%	—	—	46.0%
Hønge et al. 2016 [35]; Guinea‐Bissau	3720	1810	49.0%	—	—	120	48.0%
Naidoo et al. 2017 [36]; South Africa	4043	2978	74.0%	11.0%	TB 4%	72	74.0%
Gunda et al. 2017 [37]; Tanzania	723	545	75.4%	57.4%		48	75.4%
Gesesew et al. 2018 [38]; Ethiopia	4900	3607	73.6%	54.3%	TB 28%	49	36.5%
Luma et al. 2018 [39]; Cameroon	1324	1188	63.7%	58.2%	TB 21%		89.7%
Benzekri et al1; 2019 [40]; Senegal	128	83	52.8%	65.0%	—	12	65.0%
Lifson et al. 2019 [23]; Botswana	1559	554	39.0%	41.0%	—		60.0%
Mupfumi et al. 2019 [41]; Botswana	20,509	7166	35.0%	—	TB 2%	20 (6, 37)	35.0%
Benzekri et al. 2019 [42]; Senegal	144	102	55.0%	53.0%	—		71.0%
Lebelonyane et al. 2020 [24]; Botswana	2499	430	17.2%	—	—	12	17.2%
Kerschberger et al. 2020 [43]; Eswatini	2782	943	29.7%	13.8%	TB 7%	36	33.9%
Magro et al. 2021 [44]; Mozambique	893	416	46.6%	14.8%	—	—	46.6%
Musengimana et al. 2022 [45]; Rwanda	555	61	58.0%	—	—	18	11.0%